Oppenheimer Lowers Prestige Consumer Healthcare (NYSE:PBH) Price Target to $65.00

Prestige Consumer Healthcare (NYSE:PBH) had its price target dropped by Oppenheimer from $77.00 to $65.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price target suggests a potential upside of 23.75% from the stock’s previous close.

Several other brokerages have also commented on PBH. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, April 21st. Jefferies Financial Group lowered their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $74.75.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $52.53 on Thursday. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $2.49 billion, a P/E ratio of 13.90, a P/E/G ratio of 1.64 and a beta of 0.40. The business has a fifty day simple moving average of $60.23 and a two-hundred day simple moving average of $61.92. Prestige Consumer Healthcare has a 12 month low of $51.24 and a 12 month high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02). The firm had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business’s quarterly revenue was down 2.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.22 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 2,553 shares of company stock valued at $151,444. 1.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently bought and sold shares of the business. UMB Bank n.a. increased its holdings in Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares in the last quarter. Bayforest Capital Ltd bought a new stake in Prestige Consumer Healthcare in the 4th quarter worth about $29,000. First Horizon Corp bought a new stake in Prestige Consumer Healthcare in the 3rd quarter worth about $32,000. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after buying an additional 283 shares in the last quarter. Finally, Torren Management LLC bought a new stake in Prestige Consumer Healthcare in the 4th quarter worth about $35,000. 99.95% of the stock is currently owned by institutional investors.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Oppenheimer kept an Outperform rating on PBH, even after trimming its price target to $65 from $77, suggesting the stock still has upside from recent levels. Article source
• Neutral Sentiment: Analysts continue to see a reasonable earnings trajectory for PBH, with consensus full-year EPS at $4.54 and Zacks projecting $4.76 for FY2027 and $5.05 for FY2028.
• Neutral Sentiment: A broader analyst note highlighted upcoming Q4 earnings expectations, but no new company guidance or major business update was reported in the article. Article source
• Negative Sentiment: Zacks Research cut EPS estimates for PBH, including lowering Q2 2028 estimates to $1.24 from $1.30 and trimming FY2027/FY2028 forecasts slightly, which can signal softer long-term expectations.
• Negative Sentiment: Insider selling added to the cautious tone: VP Jeffrey Zerillo sold shares in two May 5 transactions, including 1,207 shares and 346 shares, both disclosed under a pre-arranged trading plan.
• Negative Sentiment: PBH’s latest earnings report missed expectations, with EPS of $1.14 versus $1.16 expected and revenue of $283.44 million versus $286.93 million estimated, while revenue fell 2.4% year over year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).